These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 15108355

  • 1. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
    Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E, Brazier M.
    J Cell Biochem; 2004 May 15; 92(2):285-95. PubMed ID: 15108355
    [Abstract] [Full Text] [Related]

  • 2. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, Kim HH.
    Free Radic Biol Med; 2006 May 01; 40(9):1483-93. PubMed ID: 16632109
    [Abstract] [Full Text] [Related]

  • 3. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.
    J Bone Miner Res; 2003 Dec 01; 18(12):2159-68. PubMed ID: 14672351
    [Abstract] [Full Text] [Related]

  • 4. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B, Itzstein C, Delmas PD, Chenu C.
    J Cell Biochem; 2003 Oct 01; 90(2):424-36. PubMed ID: 14505357
    [Abstract] [Full Text] [Related]

  • 5. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H, Murakami A, Aggarwal BB.
    Mol Cancer Res; 2006 Apr 01; 4(4):275-81. PubMed ID: 16603641
    [Abstract] [Full Text] [Related]

  • 6. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
    Ren W, Li XH, Chen BD, Wooley PH.
    J Orthop Res; 2004 Jan 01; 22(1):21-9. PubMed ID: 14656655
    [Abstract] [Full Text] [Related]

  • 7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 01; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.
    Biochem Biophys Res Commun; 2005 Apr 15; 329(3):839-45. PubMed ID: 15752732
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF.
    Biochem Pharmacol; 2005 Jul 15; 70(2):300-7. PubMed ID: 15919055
    [Abstract] [Full Text] [Related]

  • 12. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
    Yamaguchi M, Uchiyama S.
    Int J Mol Med; 2004 Jul 15; 14(1):81-5. PubMed ID: 15202020
    [Abstract] [Full Text] [Related]

  • 13. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
    Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Löeffler M, Kodama T, Kurosawa H, Taniguchi T.
    Arthritis Rheum; 2004 Mar 15; 50(3):794-804. PubMed ID: 15022321
    [Abstract] [Full Text] [Related]

  • 14. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.
    Life Sci; 2007 Mar 13; 80(14):1311-8. PubMed ID: 17306833
    [Abstract] [Full Text] [Related]

  • 15. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production.
    Yip KH, Zheng MH, Steer JH, Giardina TM, Han R, Lo SZ, Bakker AJ, Cassady AI, Joyce DA, Xu J.
    J Bone Miner Res; 2005 Aug 13; 20(8):1462-71. PubMed ID: 16007343
    [Abstract] [Full Text] [Related]

  • 16. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 13; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
    Uchiyama S, Yamaguchi M.
    Biochem Pharmacol; 2004 Apr 01; 67(7):1297-305. PubMed ID: 15013845
    [Abstract] [Full Text] [Related]

  • 18. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K.
    Biochem Biophys Res Commun; 2005 Mar 04; 328(1):91-7. PubMed ID: 15670755
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.